Drug Discovery Biology

Megan Gibbs Ph.D., BscPharm, FCP, Vice President and Global Head, Clinical Pharmacology & Quantitative Pharmacology Astrazeneca

TARGET IDENTIFICATION & HIT VALIDATION
Integrated Omics Approaches for Target Identification and Validation: Harnessing the power of integrative analyses that combine genomics, proteomics, metabolomics, and other omics data to identify and validate drug targets

DMPK / ADME & TOXICOLOGY
Integration of In Vitro and In Silico ADME Models: Combining in vitro ADME assays with computational models to enhance the prediction of drug properties and optimize drug discovery processes.

IN VIVO AND IN VITRO PHARMACOLOGY
In Vivo-like In Vitro Systems: The Quest for More Physiologically Relevant Drug Screening

IN SILICO BIOLOGY
Unraveling Drug-Target Interactions: Advancements in In Silico Modeling and Simulation

STRUCTURAL BIOLOGY AND BIOPHYSICS
Structural Biology and Biophysics for the next generation of First-in-Class targets

STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
Why integrating deep scientific expertise matched with operational and business strategy is key for attracting investment in early stage drug discovery

TARGET IDENTIFICATION & HIT VALIDATION
Biophysical Methods in the realm of “Target Identification & Hit Validation”

DMPK / ADME & TOXICOLOGY

IN VIVO AND IN VITRO PHARMACOLOGY
Preclinical Discovery Strategies for Enhanced Clinical Outcomes

IN SILICO BIOLOGY
Lipid Gpcrs Structural And Computational Approach: Advantages, Challenges, Limitations And New Modalities In Drug Discovery

STRUCTURAL BIOLOGY AND BIOPHYSICS

STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
The Client is Always Right = The Client is Never Wrong!

TARGET IDENTIFICATION & HIT VALIDATION
Targeting Undruggable Proteins: Exploring innovative strategies, including small-molecule approaches, PROTACs, and RNA-based therapeutics, for targeting traditionally challenging or “undruggable” proteins

DMPK / ADME & TOXICOLOGY
Emerging Technologies for ADME and Toxicology: Highlighting cutting-edge technologies, such as high-content screening, omics-based approaches, and imaging techniques, for improved ADME profiling and toxicity assessment

IN VIVO AND IN VITRO PHARMACOLOGY
Improving Translatable Pre-Clinic Models In-Vitro & In-Vivo Pharmacology for Better Characterization of Properties and Drug Leads

IN SILICO BIOLOGY
“RWE and OMICs data analytics: Defining the Right Indication and Population and Increasing the Chances of Success.”

STRUCTURAL BIOLOGY AND BIOPHYSICS
Advancing Drug Discovery Through Structural Biology: Exploring Structure-Guided Computational Approaches

STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
Navigating The Constantly Changing Market To Raise Funds And Refine R&D Strategy

TARGET IDENTIFICATION & HIT VALIDATION
Challenges and Opportunities of Targeting RNAs with Small Molecules

DMPK / ADME & TOXICOLOGY
Toxicity Biomarkers and Safety Assessment: Discussion of the latest advancements in identifying and validating toxicity biomarkers for early detection and prediction of drug induced toxicities

IN VIVO AND IN VITRO PHARMACOLOGY
Predictive Models for Drug Efficacy in Neuropharmacology: Leveraging In Vivo and In Vitro Data

IN SILICO BIOLOGY
Artificial Intelligence in Drug Design: From Generative Models to Reinforcement Learning

STRUCTURAL BIOLOGY AND BIOPHYSICS
Structural Biology Beyond Purified Proteins -Leveraging Structure Predictive Technologies to Aid High-Resolution – Cryo-EM Based Technologies

STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
Maximizing Capital Efficiency By Balancing Internal Capabilities And External CRO’s